<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760873</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20181169</org_study_id>
    <nct_id>NCT04760873</nct_id>
  </id_info>
  <brief_title>Cryotherapy for GAVE</brief_title>
  <acronym>GAVE Cryo</acronym>
  <official_title>Gastric Antral Vascular Ectasia Treatment With Balloon Cryotherapy: A Multicenter Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Long Island Jewish Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric antral vascular ectasia (GAVE) is a condition that can lead to blood loss in the&#xD;
      gastrointestinal tract and low blood counts or anemia. 1,2 GAVE is commonly associated with&#xD;
      liver disease, kidney disease and autoimmune immune problems, but can also be seen in&#xD;
      patients without those problems. 2-4 It is common for GAVE to cause hospitalization of&#xD;
      patients and significant blood transfusion requirements. Given these problems, effective&#xD;
      treatment of GAVE is needed to reduce these potential problems.&#xD;
&#xD;
      These treatments are performed by a gastroenterologist through a flexible endoscope most&#xD;
      often with argon plasma coagulation (APC).5-7 APC is only partially successful at eradicating&#xD;
      GAVE and often entails repeated endoscopic procedures. Therapy with APC can also cause&#xD;
      ulceration at times resulting in acute bleeding. Cryoablation is an attractive alternative to&#xD;
      APC as it should not cause increased blood loss and case reports suggest that ablation may be&#xD;
      achieved with limited number of endoscopic sessions. Prior problems with endoscopic&#xD;
      cryotherapy include the high flow of gas and risk of perforation.8,9 A recent retrospective&#xD;
      investigation by this group has evaluated the first generation cryotherapy balloon,&#xD;
      demonstrating clinical safety and efficacy for GAVE.10 A new balloon cryotherapy spray device&#xD;
      was recently developed and does not require venting. In this study we plan to prospectively&#xD;
      evaluate the use of balloon cryotherapy to treat GAVE. We predict that the therapeutic&#xD;
      response of balloon cryotherapy will be greater than 80% effective at achieving clinical&#xD;
      success or the loss of overt bleeding and need for packed red blood cell (PRBC) transfusion&#xD;
      at 6 months after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric antral vascular ectasia (GAVE), classically termed &quot;watermelon stomach,&quot; is a&#xD;
      condition of chronic acute blood loss in the gastrointestinal (GI) tract and can lead to&#xD;
      common utilization of packed red blood cell (PRBC) transfusion. This condition occurs in 0.3%&#xD;
      of endoscopic studies and 4% of studies performed for chronic or acute blood loss anemia.1,2&#xD;
      GAVE is commonly associated with autoimmune disease in 60% of cases and chronic liver disease&#xD;
      in 30% of cases.2-4 Given the association with chronic liver disease, GAVE can be mistaken&#xD;
      for other GI pathologies such as portal hypertensive gastropathy (PHG).11,12 Therefore,&#xD;
      identification of GAVE is important in the management of this condition.&#xD;
&#xD;
      Historically there have been 1 series highlighting the use of a monopolar probe and heater&#xD;
      probe to treat GAVE. As these therapies have a low depth of thermal penetration, these&#xD;
      therapies are not commonly utilized for GAVE.13,14 The most commonly implemented endoscopic&#xD;
      therapy is argon plasma coagulation (APC). Among the largest studies of APC, the efficacy for&#xD;
      treatment of GAVE is variable5,6 Additional outcomes include a reduction in the number of&#xD;
      PRBC transfused in patients with GAVE that were treated with APC.7 In addition to APC,&#xD;
      radiofrequency ablation (RFA) has also been evaluated in the setting of GAVE, leading to a&#xD;
      decrease in the transfusions needed during follow-up.15 Similarly, cryotherapy using a spray&#xD;
      catheter has been evaluated for GAVE.8,9 In these studies, the patients did demonstrate&#xD;
      endoscopic improvement, lower transfusion requirements, and normalization of their&#xD;
      hemoglobin. Despite, these results, the spray cryotherapy device requires the use of a&#xD;
      venting tube to prevent complications and carries with it technical limitations that can make&#xD;
      ablation difficult. Our study group, which includes University Hospitals, Case Western&#xD;
      Reserve, Long Island Jewish Medical Center, Geisinger Medical Center, Columbia University&#xD;
      Medical Center and The Cleveland Clinic Foundation of America This group has recently&#xD;
      evaluated the first generation balloon cryotherapy device for GAVE, demonstrating efficacy&#xD;
      and safety.10 Therefore, in this study we set out to prospectively evaluate the efficacy of a&#xD;
      new balloon cryotherapy device for the treatment of GAVE. We predict that balloon cryotherapy&#xD;
      will lead to greater than 80% clinical success (need for PRBC transfusion and absent overt&#xD;
      bleeding).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">February 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects with GAVE will undergo therapy with a cryotherapy device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>6 months</time_frame>
    <description>defined by the absence of PRBC transfusions and clinical evidence of bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>6 months</time_frame>
    <description>defined as the ability to treat &gt; 75% of the endoscopic area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic success</measure>
    <time_frame>6 months</time_frame>
    <description>defined as resolution of &gt; 75% of the visible GAVE endoscopic surface</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/total number of PRBC transfused</measure>
    <time_frame>6 months</time_frame>
    <description>transfusion of packed red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>6 months</time_frame>
    <description>change in the lab test hemoglobin in grams/deciLiter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure</measure>
    <time_frame>6 months</time_frame>
    <description>defined as the need for additional ablative modalities to achieve the primary study outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>GAVE - Gastric Antral Vascular Ectasia</condition>
  <condition>Bleeding</condition>
  <condition>Bleeding Gastric</condition>
  <arm_group>
    <arm_group_label>Cryotherapy for GAVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo cryotherapy for GAVE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cryotherapy</intervention_name>
    <description>cryotherapy is a freeze spray that will be applied to GAVE for bleeding</description>
    <arm_group_label>Cryotherapy for GAVE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have GAVE&#xD;
&#xD;
          2. Have had treatment discussion with non-study team member (physician or GI advanced&#xD;
             practice provider) of alternatives and have elected Cryotherapy&#xD;
&#xD;
          3. Patients with signs of GI bleeding defined as hemoglobin drop &gt; 2 grams/dL, need for&#xD;
             PRBC transfusion or overt bleeding (melena, hematemesis, hematochezia)&#xD;
&#xD;
          4. Patients undergoing EGD with Ablation for GAVE (treatment naïve, RFA, banding, APC&#xD;
             failures)&#xD;
&#xD;
          5. Patients who underwent their last ablation at least 4 weeks prior&#xD;
&#xD;
          6. Platelet count &gt; 40,000&#xD;
&#xD;
          7. International normalized ratio (INR) &lt; 1.5&#xD;
&#xD;
          8. Age &gt; 18 years and &lt; 90 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years OR &gt; 90 years&#xD;
&#xD;
          2. Inability to obtain consent&#xD;
&#xD;
          3. Anticoagulants or anti-platelet agents use (excluding aspirin) within the last 7-10&#xD;
             days&#xD;
&#xD;
          4. Platelet count &lt; 40,000&#xD;
&#xD;
          5. INR &gt; 1.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaffer Mok</last_name>
    <phone>4404065500</phone>
    <email>Shaffer.Mok@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Trindade, MD</last_name>
      <phone>718-470-7281</phone>
      <email>arvind.trindade@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center-NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amrita Sethi, MD</last_name>
      <phone>212-305-1909</phone>
      <email>as3614@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaffer Mok</last_name>
      <phone>440-406-5500</phone>
      <email>Shaffer.Mok@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation of America</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashanthi Thota, MD</last_name>
      <phone>216-444-0780</phone>
      <email>thotap@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Diehl, MD</last_name>
      <phone>570-214-4885</phone>
      <email>dldiehl@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Harshit Khara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dulai GS, Jensen DM, Kovacs TO, Gralnek IM, Jutabha R. Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension. Endoscopy. 2004 Jan;36(1):68-72.</citation>
    <PMID>14722858</PMID>
  </reference>
  <reference>
    <citation>Jabbari M, Cherry R, Lough JO, Daly DS, Kinnear DG, Goresky CA. Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology. 1984 Nov;87(5):1165-70.</citation>
    <PMID>6332757</PMID>
  </reference>
  <reference>
    <citation>Lee FI, Costello F, Flanagan N, Vasudev KS. Diffuse antral vascular ectasia. Gastrointest Endosc. 1984 Apr;30(2):87-90.</citation>
    <PMID>6714608</PMID>
  </reference>
  <reference>
    <citation>Tobin RW, Hackman RC, Kimmey MB, Durtschi MB, Hayashi A, Malik R, McDonald MF, McDonald GB. Bleeding from gastric antral vascular ectasia in marrow transplant patients. Gastrointest Endosc. 1996 Sep;44(3):223-9.</citation>
    <PMID>8885337</PMID>
  </reference>
  <reference>
    <citation>Roman S, Saurin JC, Dumortier J, Perreira A, Bernard G, Ponchon T. Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. Endoscopy. 2003 Dec;35(12):1024-8.</citation>
    <PMID>14648415</PMID>
  </reference>
  <reference>
    <citation>Yusoff I, Brennan F, Ormonde D, Laurence B. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy. 2002 May;34(5):407-10.</citation>
    <PMID>11972274</PMID>
  </reference>
  <reference>
    <citation>Wahab PJ, Mulder CJ, den Hartog G, Thies JE. Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy. 1997 Mar;29(3):176-81.</citation>
    <PMID>9201466</PMID>
  </reference>
  <reference>
    <citation>Kantsevoy SV, Cruz-Correa MR, Vaughn CA, Jagannath SB, Pasricha PJ, Kalloo AN. Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc. 2003 Mar;57(3):403-6.</citation>
    <PMID>12612530</PMID>
  </reference>
  <reference>
    <citation>Cho S, Zanati S, Yong E, Cirocco M, Kandel G, Kortan P, May G, Marcon N. Endoscopic cryotherapy for the management of gastric antral vascular ectasia. Gastrointest Endosc. 2008 Nov;68(5):895-902. doi: 10.1016/j.gie.2008.03.1109. Epub 2008 Jul 21.</citation>
    <PMID>18640673</PMID>
  </reference>
  <reference>
    <citation>Patel AA, Trindade AJ, Diehl DL, Khara HS, Lee TP, Lee C, Sethi A. Nitrous oxide cryotherapy ablation for refractory gastric antral vascular ectasia. United European Gastroenterol J. 2018 Oct;6(8):1155-1160. doi: 10.1177/2050640618783537. Epub 2018 Jun 12.</citation>
    <PMID>30288277</PMID>
  </reference>
  <reference>
    <citation>RIDER JA, KLOTZ AP, KIRSNER JB. Gastritis with veno-capillary ectasia as a source of massive gastric hemorrhage. Gastroenterology. 1953 May;24(1):118-23.</citation>
    <PMID>13052170</PMID>
  </reference>
  <reference>
    <citation>Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion. 2008;77(2):131-7. doi: 10.1159/000124339. Epub 2008 Apr 4. Review.</citation>
    <PMID>18391491</PMID>
  </reference>
  <reference>
    <citation>Petrini JL Jr, Johnston JH. Heat probe treatment for antral vascular ectasia. Gastrointest Endosc. 1989 Jul-Aug;35(4):324-8.</citation>
    <PMID>2788591</PMID>
  </reference>
  <reference>
    <citation>Gross SA, Al-Haddad M, Gill KR, Schore AN, Wallace MB. Endoscopic mucosal ablation for the treatment of gastric antral vascular ectasia with the HALO90 system: a pilot study. Gastrointest Endosc. 2008 Feb;67(2):324-7. doi: 10.1016/j.gie.2007.09.020.</citation>
    <PMID>18226696</PMID>
  </reference>
  <reference>
    <citation>Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol. 2013;26(1):11-22. Review.</citation>
    <PMID>24714327</PMID>
  </reference>
  <reference>
    <citation>Rey JF, Lambert R; ESGE Quality Assurance Committee. ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. Endoscopy. 2001 Oct;33(10):901-3.</citation>
    <PMID>11605605</PMID>
  </reference>
  <reference>
    <citation>Schölvinck DW, Künzli HT, Kestens C, Siersema PD, Vleggaar FP, Canto MI, Cosby H, Abrams JA, Lightdale CJ, Tejeda-Ramirez E, DeMeester SR, Greene CL, Jobe BA, Peters J, Bergman JJ, Weusten BL. Treatment of Barrett's esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy. 2015 Dec;47(12):1106-12. doi: 10.1055/s-0034-1392417. Epub 2015 Jul 9.</citation>
    <PMID>26158241</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Shaffer Mok</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>GAVE</keyword>
  <keyword>cryotherapy</keyword>
  <keyword>bleeding</keyword>
  <keyword>stomach</keyword>
  <keyword>gastric</keyword>
  <keyword>EGD</keyword>
  <keyword>endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Antral Vascular Ectasia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Electronic health records database will allow for availability of demographic data and office-based follow-up records. ProVation MD software information will provide details regarding endoscopic parameters and intervention performed.&#xD;
Electronic records gathered for study purposes will only be available to study investigators and will be stored on an encrypted hard drive on a computer. Data will initially be entered with PHI attached so that all information can be obtained. Once all data collection is complete identifiers will be removed and random number assigned to the patients.&#xD;
Paper copies of study consents will be filled out in the endoscopy center and stored in a locked cabinet in the endoscopy center workroom. The door to the workroom with the cabinet is locked after hours and the endoscopy center is locked after hours as well.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

